Louise Rodino-Klapac - 18 Nov 2024 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Head of R&D, CSO
Signature
/s/ Ryan Brown as Attorney-in-Fact for Louise Rodino-Klapac
Issuer symbol
SRPT
Transactions as of
18 Nov 2024
Net transactions value
-$468,973
Form type
4
Filing time
20 Nov 2024, 20:00:03 UTC
Previous filing
25 Jun 2024
Next filing
13 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Tax liability $468,973 -4,558 -6.3% $102.89 67,630 18 Nov 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021.
F2 Amount of Securities Beneficially Owned includes 47 shares purchased under the Company's registered Employee Stock Purchase Plan on August 30, 2024.